References for Chapter 15

Ranolazine

A Piperazine Derivative

William H. Frishman, MD
James J. Nawarskas, PharmD
Joe R. Anderson, PharmD

18. Lopaschuk GD, Belke DD, Gamble J, et al. Regulation of fatty acid oxidation in the mammalian...


42. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-el-
References to Chapter 15


55. CV Therapeutics, Inc. CV Therapeutics announces preclinical data evaluating ranolazine and dobutamine in a model of CHF. Available at http://www.cvtx.com.


